Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Inclusion Criteria: Patients must meet the following criteria to be included in this study: * Signed Consent Form * High-risk clinically isolated syndrome or relapsing MS Diagnosis (based on 2017 International Panel Criteria) * Age 18-50 inclusive * Screening within 90 days of first clinical demyelinating event typical of MS with 1 or more inactive lesions typical of MS * No prior MS disease modifying therapy * No corticosteroids within 7 days of first ocrelizumab treatment * EDSS \< 4.0 * A negative urine or serum pregnancy test must be available for premenopausal women and for women \<12 months after the onset of menopause, unless they have undergone surgical sterilization. * Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use one method of contraception with a failure rate of \<1% per year or a barrier method supplemented with spermicide. Contraception must continue for the duration of study treatment and for at least 24 weeks after the last dose of study treatment. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause of other than menopause), and has not undergone surgical sterilization (removal of the ovaries and/or uterus). * Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tube ligation, male sterilization, established hormonal contraceptive…